Biovitrum Announces Future Roadmap - Increased Focus on Specialist Care Diseases
At its Capital Markets Day in Stockholm, the Swedish biopharma company Biovitrum announced its roadmap for creating long term value. The three corner stones of the new strategy are:
- Re-focus R&D portfolio towards projects in diseases treated by specialists, capitalizing more on its biopharmaceutical competence.
- Develop in-house specialist care projects all the way to the market and out-license primary care R&D projects.
- Increase revenues and expand the portfolio of marketed products through geographical expansion and by acquiring new products.
The reasoning behind the new strategy was described by Biovitrum's CEO Martin Nicklasson. In summary, Nicklasson highlighted that there are many specialist care areas with high unmet medical needs with a favourable access to market and requiring less extensive development programmes. In addition, marketing and sales effort will be more focused and less costly. It also enlarges the medical scope since both biopharmaceuticals and small molecules can be pursued.
Biovitrum also announced the exercise of its option to partner, with Syntonix/Biogen Idec, on Factor VIIIFc with prolonged half-life for the treatment of hemophilia A, aiming at significantly improving patient convenience.
Other news from the department business & finance
